Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/04/2022 -- Results Q2 2022 -- 0.83 --
08/04/2022 -- Earnings Call Q2 2022 -- -- --
02/02/2022 -- Results Q4 2021 0.72 0.72 0.74%
02/02/2022 07:00 EST Earnings Call Q4 2021 -- -- --
11/03/2021 -- Results Q3 2021 -- 0.80 --
11/03/2021 08:00 EST Earnings Call Q3 2021 -- -- --
08/06/2021 07:00 EST Earnings Call Q2 2021 -- -- --
08/04/2021 -- Results Q2 2021 0.84 0.76 10.47%
*Estimated Date/Time

Earnings

Next Report Date 08/04/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 02/02/2022
Beat/Miss Upgrade
Return Since 6.20%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
URL https://www.novonordisk.com
Investor Relations URL https://www.novonordisk.com/investors.html
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Growth
Next Earnings Release Aug. 04, 2022
Last Earnings Release Feb. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 25, 2022

Dividends

Dividend Per Share (TTM) 1.578
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.99
Yield to Sector 0.661
Yield to Industry 2.022
Last Dividend Amt. 1.022
Dividend Frequency Semi-Annually
Last Ex-Dividend Date Mar. 25, 2022
Yield (TTM) 1.40%
Forward Yield 1.40%
Payout Ratio 46.76%
Cash Payout Ratio 38.81%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
39.32%
-36.56%
54.26%
-11.88%
28.69%
23.31%
63.39%
1.07%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.31%
25.37%
-10.37%
17.83%
40.45%
16.15%
31.06%
66.08%
18.77%
--
10.48%
97.92%
56.39%
122.1%
19.88%
-19.34%
-32.29%
--
--
--
-14.63%
186.0%
8.25%
-40.62%
-34.61%
-8.79%
-21.05%
5.09%
-78.80%
18.77%
8.41%
-15.08%
-24.96%
As of June 24, 2022.

Profile

Edit
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
URL https://www.novonordisk.com
Investor Relations URL https://www.novonordisk.com/investors.html
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Growth
Next Earnings Release Aug. 04, 2022
Last Earnings Release Feb. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 25, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
LIFE.TO 11.38M USD 4.89%
PPH 24.72M USD 4.83%
PJHRX 75.86M USD 4.46%
AMIGX 110.64M USD 3.49%
THW 17.05M USD 3.09%
HRINX 77.40M USD 1.88%
CHW 11.83M USD 1.59%
LGLQX 98.52M USD 1.48%
ETG 22.54M USD 1.27%
DFALX 57.91M USD 1.06%
AVDE 11.04M USD 0.80%
DFIEX 169.69M USD 0.54%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter NVO Tweets